Bloom Night

Concept

A comprehensive offering for Myopia Management

Goal

  • To provide a wide range of approved products for Myopia Control
  • To promote safe and hygienic lens wear
  • To help patients be compliant with their myopia treatment
  • To help practitioners effectively monitor and treat their patients over their lifetime

What Is Myopia?

Myopia, also known as near- or short-sightedness, is the most common refractive error and the major cause of vision impairment worldwide1,2. Globally, it is recognized as a significant public health concern associated with increased ocular-related morbidity and considerable healthcare costs3-6. It affects approximately 30% of the world's population and its prevalence has been forecast to affect about 50% of the world's population by 20501. The prevalence of myopia in young adolescents has been increasing in recent decades to about 30% in industrialized societies of the West and epidemic levels of over 90% in some parts of Far East Asia1,7-12.

Myopia is a condition in which incoming light focuses in front of, rather than on, the retina as a result of the eye being too long for its refractive power (Figure 1)6. This causes blurred distance vision while objects at near may appear clear. Myopia normally develops during childhood and progresses until the mid to late teenage years13,14, with younger children and females showing greater annual rates of myopia progression15.

Figure 1 The image on the left shows the refractive status of an emmetropic eye where light rays entering the eye focus on the retina, whereas the image on the right represents a myopic eye where light rays entering the eye focus in front of the retina causing blurred distance vision.

What Causes Myopia?

The underlying cause behind the onset and progression of myopia is believed to be a combination of genetic and environmental factors16. Risk factors include ethnicity, number of myopic parents. time engaged in close work, lack of time spent outdoors, and country and location (ie., urban/rural of residency17-25. Of particular concern is the association of increasing levels of myopia with a higher risk of potentially blinding ocular pathologies such as glaucoma, myopic maculopathy, and vitreous and retinal detachments5,26-30.
Furthermore, high myopia has also been found to contribute to a general degradation of quality of life due to psychological, cosmetic and practical reasons31.

How Does Menicon Bloom Night Work?

Menicon Bloom Night therapy involves the overnight wear of a specially designed orthokeratology contact lens manufactured in hyper oxygen permeable Menicon Z material to ensure optimal corneal oxygenation for safe and comfortable lens wear32-36. The treatment temporarily changes the shape of the cornea by flattening and steepening the central and mid-peripheral corneal curvatures, respectively. These corneal changes occur overnight and reduce refractive error, thus eliminating the need to wear contact lenses throughout the waking hours after lenses are removed37. The new corneal shape also provides a particular optical path for incoming light that counters the ocular growth response associated with myopia development38.

Menicon Bloom Night is indicated for the correction of refractive myopia and for the control of myopia when prescribed and managed by a qualified eye care professional.


Menicon Bloom Night myopia control therapy is currently available in two different contact lens designs: Menicon Bloom Night and Menicon Bloom Night Toric. Both lens types can correct up to -4.00D of myopia, with Menicon Bloom Night Toric providing additional options for correcting higher levels of corneal and refractive astigmatism.

Seeking approval in other countries outside EU
Testing extension of range beyond -4.00D

1. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.
2. Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-e34.
3. Vitale S, Cotch MF, Sperduto R, Ellwein L. Costs of refractive correction of distance vision impairment in the United States, 1999-2002. Ophthalmology. 2006;113(12):2163-70.
4. Lim MC, Gazzard G, Sim EL, Tong L, Saw SM. Direct costs of myopia in Singapore. Eye (Lond). 2009;23(5):1086-9.
5. Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622-60.
6. Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, et al. IMI - Defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20-M30.
7. Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: a meta-analysis. Optom Vis Sci. 2015;92(3):258-66.
8. Koh V, Yang A, Saw SM, Chan YH, Lin ST, Tan MM, et al. Differences in prevalence of refractive errors in young Asian males in Singapore between 1996-1997 and 2009-2010. Ophthalmic Epidemiol. 2014;21(4):247-55.
9. Pan CW, Ramamurthy D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalmic Physiol Opt. 2012;32(1):3-16.
10. Wang TJ, Chiang TH, Wang TH, Lin LL, Shih YF. Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005. Eye (Lond). 2009;23(5):1168-9.
11. Vitale S, Sperduto RD, Ferris FL, 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol. 2009;127(12):1632-9.
12. Gilmartin B. Myopia: precedents for research in the twenty-first century. Clin Exp Ophthalmol. 2004;32(3):305-24.
13. Goss DA, Winkler RL. Progression of myopia in youth: age of cessation. Am J Optom Physiol Opt. 1983;60(8):651-8.
14. Group C. Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54(13):7871-84.
15. Donovan L, Sankaridurg P, Ho A, Naduvilath T, Smith EL, 3rd, Holden BA. Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci. 2012;89(1):27-32.
16. Tedja MS, Haarman AEG, Meester-Smoor MA, Kaprio J, Mackey DA, Guggenheim JA, et al. IMI - Myopia genetics report. Invest Ophthalmol Vis Sci. 2019;60(3):M89-M105.
17. Rose KA, Morgan IG, Smith W, Burlutsky G, Mitchell P, Saw SM. Myopia, lifestyle, and schooling in students of Chinese ethnicity in Singapore and Sydney. Arch Ophthalmol. 2008;126(4):527-30.
18. French AN, Morgan IG, Mitchell P, Rose KA. Risk factors for incident myopia in Australian schoolchildren: the Sydney adolescent vascular and eye study. Ophthalmology. 2013;120(10):2100-8.
19. Mutti DO, Hayes JR, Mitchell GL, Jones LA, Moeschberger ML, Cotter SA, et al. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest Ophthalmol Vis Sci. 2007;48(6):2510-9.
20. He M, Zheng Y, Xiang F. Prevalence of myopia in urban and rural children in mainland China. Optom Vis Sci. 2009;86(1):40-4.
21. Gwiazda J, Hyman L, Dong LM, Everett D, Norton T, Kurtz D, et al. Factors associated with high myopia after 7 years of follow-up in the Correction of Myopia Evaluation Trial (COMET) Cohort. Ophthalmic Epidemiol. 2007;14(4):230-7.
22. Pacella R, McLellan J, Grice K, Del Bono EA, Wiggs JL, Gwiazda JE. Role of genetic factors in the etiology of juvenile-onset myopia based on a longitudinal study of refractive error. Optom Vis Sci. 1999;76(6):381-6.
23. Wu MM, Edwards MH. The effect of having myopic parents: an analysis of myopia in three generations. Optom Vis Sci. 1999;76(6):387-92.
24. Rosenfield M, Gilmartin B. Myopia and nearwork. Oxford, UK.: Butterworth-Heinemann; 1998.
25. Gifford KL, Richdale K, Kang P, Aller TA, Lam CS, Liu YM, et al. IMI - Clinical management guidelines report. Invest Ophthalmol Vis Sci. 2019;60(3):M184-M203.
26. Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol. 2002;134(5):645-60.
27. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology. 2002;109(4):704-11.
28. Wong TY, Klein BE, Klein R, Knudtson M, Lee KE. Refractive errors, intraocular pressure, and glaucoma in a white population. Ophthalmology. 2003;110(1):211-7.
29. Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt. 2005;25(5):381-91.
30. Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci. 2010;51(7):3721-5.
31. Rose K, Harper R, Tromans C, Waterman C, Goldberg D, Haggerty C, et al. Quality of life in myopia. Br J Ophthalmol. 2000;84(9):1031-4.
32. Ladage PM, Yamamoto K, Ren DH, Li L, Jester JV, Petroll WM, et al. Effects of rigid and soft contact lens daily wear on corneal epithelium, tear lactate dehydrogenase, and bacterial binding to exfoliated epithelial cells. Ophthalmology. 2001;108(7):1279-88.
33. Morgan PB, Maldonado-Codina C, Efron N. Comfort response to rigid and soft hyper-transmissible contact lenses used for continuous wear. Eye Contact Lens. 2003;29(1 Suppl):S127-30; discussion S43-4, S92-4.
34. Maldonado-Codina C, Morgan PB, Efron N, Efron S. Comparative clinical performance of rigid versus soft hyper Dk contact lenses used for continuous wear. Optom Vis Sci. 2005;82(6):536-48.
35. Morgan PB, Efron N, Maldonado-Codina C, Efron S. Adverse events and discontinuations with rigid and soft hyper Dk contact lenses used for continuous wear. Optom Vis Sci. 2005;82(6):528-35.
36. Albright RA, Venuti BD, Ichijima H, Nyunt AK, Cavanagh HD. Postmarket surveillance of Menicon Z rigid gas-permeable contact lenses for up to 30 days continuous wear in the United States. Eye Contact Lens. 2010;36(5):241-4.
37. Swarbrick HA. Orthokeratology review and update. Clin Exp Optom. 2006;89(3):124-43.
38. Smith EL, 3rd. Optical treatment strategies to slow myopia progression: effects of the visual extent of the optical treatment zone. Exp Eye Res. 2013;114:77-88.

Menicon Co., Ltd.

21-19, Aoi 3, Naka-ku, Nagoya 460-0006 Japan

Tel +81-(0)52-935-1515

overseas-contact@menicon.co.jp

This website uses cookies to create the most secure and effective website (Use of Cookieswindow).
By using this website, you are deemed to have agreed to the use of cookies. Privacy Policy